Takeda’s CD and UC Therapy Receives Positive Reaction from U.S. Gastroenterologists

Takeda’s CD and UC Therapy Receives Positive Reaction from U.S. Gastroenterologists
One month after the launch of Entyvio, a new treatment for moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD), the therapy is already becoming a popular prescription among gastroenterologists in the United States, according to a survey conducted by the largest pharmaceutical company in Japan and developer of the therapy, Takeda Pharmaceuticals. The injection, which

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *